Cargando…
Identification of a novel COL7A1 variant associated with dystrophic epidermolysis bullosa pruriginosa responding effectively to dupilumab
BACKGROUND: Variants in COL7A1 cause an extremely rare and clinically heterogeneous syndrome known as dystrophic epidermolysis bullosa pruriginosa (DEB‐Pr). Duplilumab, a fully humanized anti‐IL‐4Ra monoclonal antibody, can inhibit IL‐4 and IL‐13‐driven signaling. METHODS: Ethical Compliance: Follow...
Autores principales: | Zhao, Caichou, Cao, Shuanglin, Gao, Xinghua, Xu, Xuegang, Gu, Lixiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655508/ https://www.ncbi.nlm.nih.gov/pubmed/37676173 http://dx.doi.org/10.1002/mgg3.2258 |
Ejemplares similares
-
Epidermolysis bullosa pruriginosa responding to dupilumab
por: Clawson, Rebecca C., et al.
Publicado: (2021) -
Misdiagnosed dystrophic epidermolysis bullosa pruriginosa: A case report
por: Wang, Zi, et al.
Publicado: (2021) -
An Incompletely Penetrant Novel Mutation in COL7A1 Causes Epidermolysis Bullosa Pruriginosa and Dominant Dystrophic Epidermolysis Bullosa Phenotypes in an Extended Kindred
por: Yang, Catherine S, et al.
Publicado: (2012) -
Familial Epidermolysis Bullosa Pruriginosa
por: Trivedi, Madhvi, et al.
Publicado: (2022) -
Novel heterozygous COL7A1 mutation in a patient with de-novo dominant dystrophic epidermolysis bullosa pruriginosa
por: Rakasiwi, Tasya, et al.
Publicado: (2021)